Aneta Neskoromna-Jędrzejczak, Katarzyna Bogusiak, Krzysztof Chojnowski, Marta Robak and Jacek Treliński
subcommittee of factor VIII and factor IX of the scientific and standarization committee of the International Society on Thrombosis and Haemostasis Thromb Haemost. 2001 85 560
 Lehmann-Kopydlowska M, Zawilska K. Dental guidelines in congenital hemophilia A and B. Czas Stomatol. 2010;63(6):345-357. Lehmann-Kopydlowska M Zawilska K. Dental guidelines in congenital hemophilia A and B Czas Stomatol. 2010 63 6 345 357
 Bjorkman S, Carlsson M, Berntop E. Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation
Paweł Łaguna, Anna Klukowska, Jarosław Ćwikła and Michał Matysiak
children with severe haemophilia A: a protocol from the UK Haemophilia Centre Doctors’ Organisation Inhibitor and Paediatric Working Parties. Haemophilia 2017;23:654–59. 28574205 10.1111/hae.13264
Collins P Chalmers E Alamelu J et al First-line immune tolerance induction for children with severe haemophilia A: a protocol from the UK Haemophilia Centre Doctors’ Organisation Inhibitor and Paediatric Working Parties Haemophilia 2017 23 654 59
 Ananyeva NM, Lacroix-Esmazes S, Hauser CA. Inhibitors in hemophilia A: mechanisms of inhibitor
detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 2007;13:317-322. 10.1111/j.1365-2516.2007.01450.x Sahud MA Pratt KP Zhukov O Qu K Thompson AR. ELISA system for detection of immune responses to FVIII. a study of 246 samples and correlation with the Bethesda assay Haemophilia 2007 13 317 322
 Tiede A, Werwitzke S, Scharf RE: Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014;40:803-811. 10.1055/s-0034-1390004 Tiede A Werwitzke S Scharf
arthroplasty. Haemophilia 2011;17:999–1004.
Viliani T Zambelan G Pandolfi C et al In‐patient rehabilitation in haemophilic subjects with total knee arthroplasty Haemophilia 2011 17 999 1004
 Stephensen D, Bladen M, McLaughlin P. Recent advances in musculoskeletal physiotherapy for haemophilia. Ther Adv Hematol 2018;9:227–37. 10.1177/2040620718784834 30181843
Stephensen D Bladen M McLaughlin P Recent advances in musculoskeletal physiotherapy for haemophilia Ther Adv Hematol 2018 9 227 37
 Jaworski JM, Zawojski A, Zdziarska J
neurological toxicities have been also reported with ipilimumab, such as Guillain-Barre syndrome ( 57 ). In addition, asymptomatic laboratory elevation of amylase and lipase that does not fulfil the criteria of acute pancreatitis is a common finding, and its clinical significance is unknown ( 7 , 12 ). Red cell aplasia, neutropenia, thrombocytopenia, and acquired hemophilia A have been described in patients treated with ipilimumab ( 58 - 59 ).
Discussion and future directions
Treatment with ICIs has dramatically changed the landscape of advanced cancer treatment
Darja Pavlin, Maja Cemazar, Andrej Cör, Gregor Sersa, Azra Pogacnik and Natasa Tozon
. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17 : 890-7.
Fewell JG, MacLaughlin F, Mehta V, Gondo M, Nicol F, Wilson E, et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther 2001; 3 : 574-83.
Draghia-Akli R, Hahn KA, King GK, Cummings KK, Carpenter RH. Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 2002; 6 : 830
Teresa Iwaniec, Joanna Zdziarska and Artur Jurczyszyn
typical for MM (84%). Complete blood count (CBC) abnormalities include normocytic anemia (ca 70%), rouleaux-forming erythrocytes (50%), leukopenia and thrombocytopenia (20% and 5%, respectively) [ 1 , 2 ].
It is known that plasma cell dyscrasias can be accompanied by both thrombotic and hemorrhagic events, including venous thrombosis, acquired von Willebrand syndrome and acquired hemophilia. Increased risk of venous thromboembolism in myeloma patients is associated with increased FVIII and von Willebrand factor activity [ 3 , 4 , 5 ], decreased protein S activity